Becton, Dickinson and Company $BDX Shares Sold by Lbp Am Sa

Key Points

• Lbp Am Sa reduced its position in Becton, Dickinson and Company (BDX) by 7.1% in the second quarter, holding 318,287 shares after selling 24,198 shares.
• Recent price target changes by analysts include Argus raising it to $230.00, while Barclays lowered theirs to $241.00, indicating varying bullishness about the stock.
• Becton, Dickinson and Company reported a 10.4% year-over-year revenue increase to $5.51 billion and an earnings per share of $3.68, surpassing analysts' expectations.

Lbp Am Sa lowered its position in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 7.1% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 318,287 shares of the medical instruments supplier's stock after selling 24,198 shares during the period. Becton, Dickinson and Company comprises approximately 0.8% of Lbp Am Sa's investment portfolio, making the stock its 27th biggest position. Lbp Am Sa owned approximately 0.11% of Becton, Dickinson and Company worth $54,825,000 at the end of the most recent quarter.

Several other hedge funds have also recently modified their holdings of BDX. Saudi Central Bank acquired a new position in shares of Becton, Dickinson and Company during the 1st quarter worth about $26,000. Smallwood Wealth Investment Management LLC acquired a new position in shares of Becton, Dickinson and Company during the 1st quarter worth about $27,000. Alpine Bank Wealth Management acquired a new position in shares of Becton, Dickinson and Company during the 1st quarter worth about $29,000. Cornerstone Planning Group LLC raised its position in shares of Becton, Dickinson and Company by 341.4% during the 1st quarter. Cornerstone Planning Group LLC now owns 128 shares of the medical instruments supplier's stock worth $29,000 after purchasing an additional 99 shares during the last quarter. Finally, Kelly Lawrence W & Associates Inc. CA acquired a new position in shares of Becton, Dickinson and Company during the 1st quarter worth about $31,000. Institutional investors and hedge funds own 86.97% of the company's stock.

Analysts Set New Price Targets

Several research analysts recently weighed in on the stock. Argus upped their price target on shares of Becton, Dickinson and Company from $220.00 to $230.00 in a research report on Monday, September 15th. Barclays dropped their price objective on shares of Becton, Dickinson and Company from $261.00 to $241.00 and set an "overweight" rating for the company in a research note on Tuesday, June 3rd. Wells Fargo & Company upped their price objective on shares of Becton, Dickinson and Company from $172.00 to $184.00 and gave the company an "equal weight" rating in a research note on Friday, August 8th. Royal Bank Of Canada started coverage on shares of Becton, Dickinson and Company in a research note on Thursday, September 25th. They set a "sector perform" rating and a $211.00 price objective for the company. Finally, Wall Street Zen raised shares of Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a research note on Saturday, August 9th. Three research analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Hold" and a consensus target price of $205.40.

Insider Activity at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,185 shares of the stock in a transaction that occurred on Friday, July 18th. The shares were sold at an average price of $180.29, for a total transaction of $213,643.65. Following the sale, the executive vice president directly owned 4,887 shares in the company, valued at $881,077.23. This represents a 19.52% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Claire Fraser sold 917 shares of the stock in a transaction that occurred on Wednesday, September 10th. The stock was sold at an average price of $187.50, for a total transaction of $171,937.50. Following the sale, the director owned 22,226 shares in the company, valued at approximately $4,167,375. This trade represents a 3.96% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 3,023 shares of company stock worth $562,036. Company insiders own 0.36% of the company's stock.

Becton, Dickinson and Company Stock Performance

Becton, Dickinson and Company stock opened at $187.06 on Wednesday. The firm has a 50 day simple moving average of $188.55 and a 200-day simple moving average of $188.18. Becton, Dickinson and Company has a 1-year low of $163.33 and a 1-year high of $251.99. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.10 and a quick ratio of 0.62. The stock has a market cap of $53.62 billion, a price-to-earnings ratio of 33.64, a price-to-earnings-growth ratio of 1.48 and a beta of 0.27.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $3.68 earnings per share for the quarter, beating the consensus estimate of $3.40 by $0.28. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. The business had revenue of $5.51 billion during the quarter, compared to analysts' expectations of $5.50 billion. During the same quarter in the prior year, the company posted $3.50 EPS. The business's revenue for the quarter was up 10.4% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. On average, analysts expect that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 30th. Stockholders of record on Monday, September 8th were issued a $1.04 dividend. This represents a $4.16 annualized dividend and a dividend yield of 2.2%. The ex-dividend date was Monday, September 8th. Becton, Dickinson and Company's dividend payout ratio is currently 74.82%.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.